Canaccord Genuity Assumes Coverage on Optimer Pharmaceuticals (OPTR) at Buy; Near Term Growth Driven by Unmet Need

Canaccord Genuity assumes coverage on Optimer Pharmaceuticals (NASDAQ: OPTR) with a Buy. PT $21.00.

Analyst, Ritu Baral, said, "...expectation of steady revenue growth driven by unmet need and Dificid’s superior efficacy in Clostridium difficile-associated diarrhea (CDAD). We feel there is still unmet need given the relapse rates associated with other therapies, the rising incidence of CDAD, and the growing severity of the disease. Further, we think the pharmaco-economics of Dificid treatment will drive uptake over time, despite premium pricing. Our $21 target is based on a DCF of Dificid/Dificlir sales and royalties."

For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.

Shares of Optimer Pharmaceuticals closed at $15.03 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
• Evercore ISI Starts Alvotech SA (ALVO) at Outperform
• Curaleaf announces unsolicited takeover bid for Aurora Cannabis